![](https://static.biospace.com/dims4/default/32129f9/2147483647/strip/true/crop/360x180+0+0/resize/200x100!/quality/90/?url=https%3A%2F%2Fk1-prod-biospace.s3.us-east-2.amazonaws.com%2Fbrightspot%2Flegacy%2FBioSpace-Assets%2F3B5B3E7D-C8F9-46C5-B76B-725A7781052A.png)
CARGO Therapeutics
NEWS
The handful of biotechs that went public in 2023 fared well, providing hope to a cautiously optimistic sector.
Rapport Therapeutics tops this year’s list with $250 million in Series A and B financing in just six months.
The cell therapy-focused biotech will use most of the net proceeds from its initial public offering to fund Phase II clinical trials for its lead program, a novel CAR T-cell candidate.
IN THE PRESS
JOBS